What is Karen Prange’s AtriCure (ATRC) share ownership after this grant?

After receiving the 6,144-share Restricted Stock Award, Karen Prange directly holds 29,373 AtriCure common shares. This post-transaction figure reflects her direct ownership position reported in the Form 4 filing following the equity grant.

AtriCure director granted 6,144 restricted shares

AtriCure, Inc. director Karen Prange reported an equity compensation grant of common stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

AtriCure, Inc. director Karen Prange reported an equity compensation grant of common stock. She acquired 6,144 shares of AtriCure common stock at no cash cost as a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan, which will vest on the one-year anniversary of the grant date. Following this award, she holds 29,373 common shares directly.

Insider Trade Summary

Grant/Award: 6,144 shares

Grant/Award 1 txn

Insider Prange Karen

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,144	$0.00	$0.00

Holdings After Transaction: Common Stock — 29,373 shares (Direct)

Footnotes (1)

F1. The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

Key Figures

Restricted shares granted: 6,144 shares Grant price: $0.00 per share Post-grant holdings: 29,373 shares

3 metrics

Restricted shares granted 6,144 shares Restricted Stock Award to director on grant date

Grant price $0.00 per share Equity compensation, not open-market purchase

Post-grant holdings 29,373 shares Director’s direct ownership after the award

Key Terms

Restricted Stock Award, AtriCure, Inc. 2023 Stock Incentive Plan, vest

3 terms

Restricted Stock Award financial

"The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan."

A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.

AtriCure, Inc. 2023 Stock Incentive Plan financial

"The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan."

vest financial

"The shares will vest upon the one-year anniversary of the grant date."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AtriCure (ATRC) report for Karen Prange?

AtriCure reported that director Karen Prange received a grant of 6,144 shares of common stock. The award is a Restricted Stock Award issued as equity compensation, not an open-market purchase, and was granted under the AtriCure, Inc. 2023 Stock Incentive Plan.

How many AtriCure (ATRC) shares did Karen Prange acquire and at what price?

Karen Prange acquired 6,144 AtriCure common shares at a reported transaction price of $0.00 per share. This reflects a stock-based compensation grant rather than a cash purchase, as disclosed in the Form 4 insider filing.

When will Karen Prange’s new AtriCure (ATRC) restricted shares vest?

The 6,144 restricted shares granted to Karen Prange will vest on the one-year anniversary of the grant date. Until that vesting date, the award remains subject to the vesting conditions described in the Restricted Stock Award terms.

Is the AtriCure (ATRC) transaction a stock purchase or a compensation grant?

The transaction is a compensation grant, not an open-market stock purchase. Karen Prange received 6,144 common shares as a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan, with a reported price of $0.00 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/20/2026 - 12:44 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Prange Karen

(Last)

(First)

(Middle)

7555 INNOVATION WAY

(Street)

MASON

OHIO

45040-9695

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/18/2026		A		6,144⁽¹⁾	A	$0	29,373	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

Remarks:

	/s/ Allison Walker as Attorney-in-fact for Karen N. Prange	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR